WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases

Study Purpose

This phase I trial studies the side effects and best dose of WSD0922-FU for the treatment of glioblastoma, anaplastic astrocytoma, or non-small cell lung cancer that has spread to the central nervous system (central nervous system metastases). WSD0922-FU is a targeted treatment which blocks the EGFR protein

  • - a strategy that has led to a lot of benefit in patients with many different cancers.
WSD0922-FU may also be able to get into cancers in the brain and spinal cord and help patients with brain and spinal cord cancers.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Pre-Registration - Inclusion Criteria Specific to Dose Escalation Cohort - Histological confirmation of either glioblastoma, IDH wildtype (GBM), anaplastic astrocytoma, IDH wildtype (AA) or non-small cell lung cancer (NSCLC) - EGFR Status: - GBM/AA must have EGFR amplification and/or EGFRvIII mutation - NSCLC must have confirmed activating EGFR mutation (including Del19, L858R, EGFRvIII, G719A, L861Q) - Pre-Registration - Inclusion Criteria Specific to Dose Expansion Cohorts - Glioblastoma, IDH wildtype/Anaplastic astrocytoma, IDH wildtype (GBM/AA) Cohort: - Diagnosis: Histological confirmation of either glioblastoma, IDH wildtype (GBM) or anaplastic astrocytoma, IDH wildtype (AA) - EGFR status: GBM/AA must have EGFR amplification and/or EGFRvIII mutation - Brain Tumor Penetration (BTP) Cohort: - Diagnosis: Histological confirmation of either glioblastoma, IDH wildtype (GBM) or anaplastic astrocytoma, IDH wildtype (AA) - EGFR status: GBM/AA must have been previously demonstrated to have EGFR amplification and/or EGFRvIII mutation based on any prior resection - Non-Small Cell Lung Cancer Leptomeningeal Metastases (NSCLC LM) cohort: - Diagnosis: Histological confirmation of non-small cell lung cancer (NSCLC) - EGFR status: NSCLC must have confirmed activating EGFR mutation (including Del19, L858R, EGFRvIII, G719A, L861Q) - Registration -Inclusion Criteria Specific to Dose Escalation Cohort - Previous treatments: - Patients with GBM/AA must have been previously treated with radiation and temozolomide - Patients with NSCLC must have been previously treated with at least one line of single-agent therapy with an EGFR TKI e.g. gefitinib, erlotinib, afatinib, or osimertinib) and at least one line of chemotherapy (doublet chemotherapy such as carboplatin/paclitaxel, carboplatin/gemcitabine, cisplatin/paclitaxel, cisplatin/gemcitabine; single agent such as pemetrexed, gemcitabine, taxanes, or other regimens listed in the National Comprehensive Cancer Network [NCCN] guidelines) - Radiographic progression: - Patients with GBM/AA must have radiographic progression based on RANO criteria - Patients with NSCLC must have new or radiographic progression in the central nervous system (brain metastases and/or leptomeningeal metastases).
Positive confirmation of CSF cytology is both necessary and sufficient to define the presence of leptomeningeal metastases for patients in this study. Patients with positive CSF cytology and brain metastases will be categorized as "leptomeningeal metastases."
  • - Measurable disease - Eastern Cooperative Oncology Group (ECOG) 0 or 1.
For patients with NSCLC with leptomeningeal metastases, ECOG 2 is also acceptable
  • - Registration - Inclusion Criteria Specific to Dose Expansion Cohorts - Glioblastoma, IDH wildtype/Anaplastic astrocytoma, IDH wildtype (GBM/AA) Cohort: - Previous treatments: Patients must have been previously treated with radiation and temozolomide - Radiographic progression: Patients with GBM/AA must have radiographic progression based on RANO criteria - Measurable disease - Performance status: ECOG 0 or 1 for patients with GBM/AA - Brain Tumor Penetration (BTP) Cohort: - Previous treatments: Patients must have been previously treated with radiation and temozolomide - Radiographic progression: Patients with GBM/AA must have radiographic progression based on RANO criteria - Therapeutic surgical resection of GBM/AA required as part of routine clinical care - Performance status: ECOG 0 or 1 - Non-Small Cell Lung Cancer Leptomeningeal Metastases (NSCLC LM) cohort: - Previous treatments: Patients must have had either: - No prior treatment with an EGFR TKI, or - Previous EGFR TKI treatment (e.g. gefitinib, erlotinib, afatinib, or osimertinib) followed by central nervous system (CNS) disease progression without extra-CNS progression - Radiographic progression: Patients must have new or radiographic progression of leptomeningeal metastases.
Positive confirmation of CSF cytology is both necessary and sufficient to define the presence of leptomeningeal metastases for patients in this study
  • - For the NSCLC LM expansion cohort, patients must have both positive confirmation of CSF cytology and at least one site of leptomeningeal disease that can be assessed by magnetic resonance imaging (MRI) and which is suitable for repeat assessments as per the investigator's discretion - Performance Status: ECOG 0, 1, or 2 - Registration - Inclusion Criteria Common to Dose Escalation and Dose Expansion Cohorts: - Ability to understand and the willingness to sign a written informed consent document - Hemoglobin >= 9.0 g/dL (obtained =< 14 days prior to registration) - Leukocytes >= 3.0 x 10^9/L (obtained =< 14 days prior to registration) - Absolute neutrophil count >= 1.5 x 10^9/L (obtained =< 14 days prior to registration) - Platelets >= 100 x 10^9/L (obtained =< 14 days prior to registration) - International normalized ratio (INR) =< 1.5 x upper limit of normal (ULN) (obtained =< 14 days prior to registration) - Patients on a stable dose of anti-coagulation therapy will be allowed to participate if they have no signs of bleeding or clotting and the INR/prothrombin time (PT) and partial thromboplastin time (PTT)/activated (a)PTT results are compatible with an acceptable risk-benefit ratio as per the investigator's discretion - aPTT =< 1.5 x ULN (obtained =< 14 days prior to registration) - Patients on a stable dose of anti-coagulation therapy will be allowed to participate if they have no signs of bleeding or clotting and the INR/PT and PTT/aPTT results are compatible with an acceptable risk-benefit ratio as per the investigator's discretion - Total bilirubin =< 1.5 x ULN and < 3 mg/dL for patients with Gilbert's disease (obtained =< 14 days prior to registration) - Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x ULN or =< 5 x ULN if due to liver involvement by tumor (obtained =< 14 days prior to registration) - Creatinine =< 1.5 x ULN or estimated glomerular filtration rate (estimated glomerular filtration rate [eGFR]) >= 60 mL/minute (obtained =< 14 days prior to registration) - Negative pregnancy test done =< 7 days prior to registration, for persons of childbearing potential only - Provision of signed and dated written informed consent prior to any study specific procedures, sampling, and analyses - Willingness to provide mandatory blood specimens and mandatory tissue specimens for correlative research - Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study i.e., active treatment and clinical follow-up) - Male and female patients of child bearing potential must be willing to use contraception, (i.e., condoms, birth control) while on study and until 3 months after the last dose of study drug is taken - Must be willing to take light-protective measures during the study and for 2 weeks after their last dose of WSD0922-FU - Must have a minimum life expectancy of >= 3 months - Must be stable on no more than 2 mg of dexamethasone (or equivalent steroids) per day.
Steroid dose should not be adjusted during cycle 1 of therapy
  • - Must not take enzyme-inducing anticonvulsants treatment for at least 2 weeks prior to enrollment.
Patients on enzyme-inducing anticonvulsants will be changed to non-enzyme inducing anticonvulsants. Drug-drug interactions (DDI) with proton pump inhibitor (PPI), H2 blockers or antacids have not been assessed; therefore it is suggested to avoid taking those drugs together with WSD0922-FU
  • - Strong inducers and strong inhibitors of CYP3A should be discontinued at least 14 days prior to registration

    Exclusion Criteria:

    - Registration - Exclusion Criteria for Dose Escalation and Dose Expansion - Any of the following because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown: - Pregnant persons - Nursing persons - Persons of childbearing potential who are unwilling to employ adequate contraception - Any of the following prior therapies: - Any cytotoxic chemotherapy or other anticancer drugs for the treatment of advanced NSCLC from a previous treatment regimen =< 14 days prior to registration - In patients with NSCLC, treatment with an EGFR TKI (e.g., erlotinib, gefitinib, afatinib or osimertinib) within 8 days or approximately 5 x half-life, whichever is the longer, prior to registration (if sufficient wash-out time has not occurred due to schedule or PK properties, an alternative appropriate wash-out time based on known duration and time to reversibility of drug related adverse events could be agreed upon by the Investigator and Wayshine) - Radiation therapy to the brain =< 12 weeks prior to registration - Patients with GBM/AA must not have received prior anti-EGFR or EGFRvIII therapies (erlotinib, gefitinib, afatinib, osimertinib, ABT-414, ABBV-221, AMG-595, AMG-596 etc.) or prior treatment with bevacizumab - Received prior systemic biologic therapy (CAR-T, anti-PD-1 / anti-PD-L1, anti-CTLA-4, etc.) within 28 days prior to registration.
  • - Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens including uncontrolled hypertension and active bleeding diatheses, which in the investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol.
Screening for chronic conditions is not required
  • - Subjects who are human immunodeficiency virus (HIV), hepatitis virus B (HBV), and/or hepatitis virus C (HCV) positive - Uncontrolled inter-current illness including, but not limited to: - Symptomatic CNS complications that require urgent neurosurgical or medical (e.g. mannitol) intervention - Seizures requiring a change in anti-epileptic medications (addition of new anti-epileptic or increase in dose) =< 2 weeks of registration - Known intracranial hemorrhage which is unrelated to tumor - Significant medical or psychiatric illness that would interfere with compliance and ability to tolerate treatment as outlined in the protocol - Illness/social situations that would limit compliance with study requirements - Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm - Patients with a "currently active" second malignancy other than non-melanoma skin cancers and carcinoma-in-situ of the cervix.
Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for more than three years prior to registration
  • - Any of the following cardiac criteria: - A marked baseline prolongation of QT/corrected QT (QTc) interval - (e.g., repeated demonstration of a QTc interval > 480 milliseconds (ms) (Common Terminology Criteria for Adverse Events [CTCAE] grade 1) using Fridericia's QT correction formula - A history of additional risk factors for torsade de pointes (TdP) (e.g., heart failure, hypokalemia, family history of long QT syndrome) - The use of concomitant medications that prolong the QT/QTc interval - Patients confirmed to have a cis double mutation (Del19/T790M or L858R/T790M) or cis triple mutation (Del19/T790m/C797S or L858R/T790M/C797S) - Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease.
History of hypersensitivity to active or inactive excipients of WSD0922-FU or drugs with a similar chemical structure or class to WSD0922-FU - Refractory nausea and vomiting if not controlled by supportive therapy, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of WSD0922-FU - Inadequate bone marrow reserve or organ function - Patients with NSCLC LM who are unable to undergo collection of CSF

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT04197934
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 1
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Mayo Clinic
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Sani H Kizilbash
Principal Investigator Affiliation Mayo Clinic
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

OtherNIH
Overall Status Recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Anaplastic Astrocytoma, IDH-Wildtype, Glioblastoma, IDH-Wildtype, Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Central Nervous System, Metastatic Malignant Neoplasm in the Leptomeninges
Study Website: View Trial Website
Additional Details

PRIMARY OBJECTIVE:

  • I. To determine the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D) of EGFR/EGFRvIII inhibitor WSD0922-FU (WSD0922-FU) in subjects with recurrent glioblastoma, IDH wildtype (GBM), anaplastic astrocytoma, IDH wildtype (AA) and central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC).
SECONDARY OBJECTIVES:
  • I. To evaluate the incidence of treatment-emergent adverse events (TEAEs) related to WSD0922-FU.
  • II. To assess anti-tumor activity: intracranial and extracranial overall response rate (ORR), and change in tumor size compared with baseline according to Response Assessment in Neuro-Oncology (RANO) criteria for GBM/AA and Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for NSCLC.
  • III. To assess anti-tumor activity: intracranial and extracranial disease control rate (DCR) and change in tumor size compared with baseline according to RANO criteria for GBM/AA and RECIST 1.1 for NSCLC.
  • IV. To assess anti-tumor activity: intracranial and extracranial duration of response (DOR) and change in tumor size compared with baseline according to RANO criteria for GBM/AA and RECIST 1.1 for NSCLC.
  • V. To assess anti-tumor activity: intracranial and extracranial progression-free survival (PFS) and change in tumor size compared with baseline according to RANO criteria for GBM/AA and RECIST 1.1 for NSCLC.
EXPLORATORY/CORRELATIVE RESEARCH OBJECTIVES:
  • I. To investigate the presence and/or identity of the drug metabolites of WSD0922-FU, and the concentrations of these in the plasma, cerebrospinal fluid (CSF), and tumor.
  • II. To assess plasma concentration of WSD0922-FU and metabolite SN16110801P1 and pharmacokinetics (PK) parameters after single and multiple doses of WSD0922-FU.
  • III. To assess the brain tumor pharmacokinetics of WSD0922-FU and SN16110801P1 after a single dose of WSD0922-FU (Dose Expansion - Brain tumor penetration [BTP] cohort only).
  • IV. To assess cerebrospinal fluid (CSF) concentration of WSD0922-FU and SN16110801P1 after multiple doses of WSD0922-FU (Dose Expansion - NSCLC leptomeningeal metastases [NSCLC LM] cohort only).
  • V. To explore the impact of tumor markers (e.g. MGMT promoter methylation, EGFR mutation [including EGFR vIII], PTEN deletion, TP53 mutation, etc.) on clinical parameters associated with WSD0922-FU treatment.
  • VI. To evaluate and measure pharmacodynamic biomarkers of inhibition of EGFR and downstream signals in tumor samples after a single dose of WSD0922-FU (Dose Expansion Cohort - BTP cohort only).
  • VII. To evaluate the effect of food on the pharmacokinetics of single dose of WSD0922-FU in plasma (Dose Expansion - NSCLC LM cohort only).
OUTLINE: This is a dose-escalation study. DOSE ESCALATION: Patients receive WSD0922-FU orally (PO) once daily (QD) or twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. DOSE EXPANSION: Patients are assigned to 1 of 3 cohorts. COHORT I: Patients with GBM/AA receive WSD0922-FU PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. COHORT II: Patients with BTP receive a single dose of WSD0922-FU prior to surgery. Patients then undergo surgical resection of brain tumor. After surgery, patients receive WSD0922-FU PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. COHORT III: Patients with NSCLC LM receive WSD0922-FU PO on days 1 and 4 of cycle 0. Patients then receive WSD0922-FU PO BID on days 1-28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 4-6 weeks, then every 2 months until progressive disease, at progressive disease, and then every 3 months after progressive disease for up to 5 years.

Arms & Interventions

Arms

Experimental: Dose escalation (WSD0922-FU)

Patients receive WSD0922-FU PO QD or BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Experimental: Dose expansion Cohort I (WSD0922-FU)

Patients with GBM/AA receive WSD0922-FU PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Experimental: Dose expansion Cohort II (WSD0922-FU, surgery)

Patients with BTP receive a single dose of WSD0922-FU prior to surgery. Patients then undergo surgical resection of brain tumor. After surgery, patients receive WSD0922-FU PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Experimental: Dose expansion Cohort III (WSD0922-FU)

Patients with NSCLC LM receive WSD0922-FU PO on days 1 and 4 of cycle 0. Patients then receive WSD0922-FU PO BID on days 1-28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Interventions

Drug: - EGFR/EGFRvIII Inhibitor WSD0922-FU

Given PO

Procedure: - Therapeutic Conventional Surgery

Undergo surgical resection

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Mayo Clinic Arizona, Phoenix, Arizona

Status

Recruiting

Address

Mayo Clinic Arizona

Phoenix, Arizona, 85054

Site Contact

Clinical Trials Referral Office

855-776-0015

Mayo Clinic Flordia, Jacksonville, Florida

Status

Recruiting

Address

Mayo Clinic Flordia

Jacksonville, Florida, 32224

Site Contact

Clinical Trials Referral Office

855-776-0015

Mayo Clinic, Rochester, Minnesota

Status

Recruiting

Address

Mayo Clinic

Rochester, Minnesota, 55905

Site Contact

Clinical Trials Referral Office

855-776-0015

The content provided by NBTS on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation. For a full description of terms please refer to: Terms, Conditions & Privacy